Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Gene Therapy and CAR-T Meeting 2024

View overview page
4:31
T2Evolve: identifying and addressing the needs and gaps in CAR-T therapy
Carmen Sanges • 29 Feb 2024
6:06
The role of AI in medicine and how acceptance and trust in AI strategies can be fostered
Carmen Sanges • 29 Feb 2024
3:54
KCAT19: an off-the-shelf cord blood-derived allogeneic CAR-T product without genome editing
Giulia Agliardi • 26 Feb 2024
2:45
The need for alternative development pathways for CAR T-cell products
Andre Baruchel • 16 Feb 2024
1:54
Looking forward to the 50th Annual Meeting of the EBMT
Anna Sureda • 7 Mar 2024
3:32
The risk of secondary malignancies following CAR T-cell therapy: current evidence
Anna Sureda • 7 Mar 2024
1:07
Highlights from the CAR-T Meeting 2024: gaining an insight into the stages of CAR-T development
Luis-Esteban Tamariz-Amador • 20 Feb 2024
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
1:57
CAR-T in myeloma: will it provide a cure?
Borja Puertas-Martinez • 16 Feb 2024
2:16
The success of the EBMT-EHA 6th European CAR T-cell Meeting
Anna Sureda • 7 Mar 2024
2:19
First-in-human Phase I trial of AT101, a novel anti-CD19 CAR-T, in R/R NHL
Marco Ruella • 16 Feb 2024
1:46
The factors associated with poor outcomes following CAR-T in patients with myeloma
Luis-Esteban Tamariz-Amador • 20 Feb 2024
3:31
A summary of the prognostic factors that can influence the outcomes of anti-CD19 CAR-T in R/R DLBCL
Anna Sureda • 7 Mar 2024
2:40
The impact of CAR-T on the role of SCT in lymphoma
Anna Sureda • 7 Mar 2024
2:17
Improving access to advanced therapies: the access to CAR-T in Europe
Christian Chabannon • 17 Feb 2024
1:25
Improving access to CAR-T: maximizing cross-project synergy and impact of European projects
Solène Clavreul • 17 Feb 2024
The content of VJHemOnc is intended for healthcare professionals